Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
P/S ratio for Mereo BioPharma Group plc (MREO)
P/S ratio as of 2023: 152.33
According to Mereo BioPharma Group plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 152.33. At the end of 2022 the company had a P/S ratio of 248.17.
P/S ratio history for Mereo BioPharma Group plc from 2015 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 152.33 |
| 2022 | 248.17 |
| 2021 | 17.11 |
| 2020 | 2251.64 |
| 2019 | -1811.27 |
| 2018 | 0.00 |
| 2017 | -101.07 |
| 2016 | 0.00 |
| 2015 | 0.00 |